Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06338826
Other study ID # ANRS0250s-BI-LIGHT
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2024
Est. completion date February 28, 2027

Study information

Verified date March 2024
Source ANRS, Emerging Infectious Diseases
Contact Fatoumata COULIBALY
Phone 0144236110
Email fatoumata.coulibaly@anrs.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 140
Est. completion date February 28, 2027
Est. primary completion date February 28, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. HIV-1-HBV co-infection (positive HIV-1 serology associated with 2 positive HBsAg serologies within more than 6 months); 2. Age = 18 years 3. Fibroscan less than 6 months < 9kPa 4. Current daily antiretroviral tritherapy not modified for = 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from - NNRTI = efavirenz, rilpivirine, etravirine, doravirine - PI/r = atazanavir/r ou darunavir/r - INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir; 5. Absence of documented HBV and HIV genotypic resistance compromising virologic control of any of the maintenance strategies. Patients with no genotypic history may be included); 6. HIV CV < 50cp/ml for = 2 years (only 1 annual blip allowed if HIV CV < 200cp/ml and previous and subsequent viral loads are undetectable); 7. HBV CV < 10 IU/ml for = 2 years (only 1 annual blip allowed if HBV CV < 200IU/ml and if previous and subsequent viral loads are undetectable); 8. Have = 3 available measurements of HIV CV < 50cp/ml and HBV CV < 10 IU/mL over the past 24 months (including that of pre-inclusion); 9. CD4 lymphocytes > 250/mm3 at pre-inclusion; 10. ALT < 3N at pre-inclusion; 11. For women of childbearing potential, negative pregnancy test and commitment to use effective contraception throughout the trial; 12. Person affiliated with or benefiting from a social security system; 13. Free, informed, written consent, signed by the person and the investigator at the latest on the day of inclusion and before any examination carried out as part of the study (article L1122-1-1 of the Public Health Code) Exclusion Criteria: 1. HIV-2 infection; 2. HIV and/or HBV genotype not compatible with dual therapy DTG-3TC or DRVr-3TC; 3. HBeAg+; 4. Fibrosis history at stage F3-F4 in pre-therapy evaluated by PBH, fibrotest and/or fibroscan with a value of Elastometry = 9kPa; 5. Chronic active viral hepatitis C (HCV RNA positive); 6. Delta co-infection; 7. Alcohol consumption > 14 units/week for women and 21 units/week for men; 8. Current treatment with chemo- or immunotherapy (including interferon or interleukins); 9. Active opportunistic infection or acute treatment for opportunistic infection; 10. Any condition (drug use, neurological, neuropsychiatric, etc.) that, in the judgment of the investigator, may compromise patient compliance and adherence to the protocol; 11. Pregnant or breastfeeding woman or refusal of contraception; 12. Major incapacity, legal protection, guardianship or curatorship

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI
The study will include patients under current daily antiretroviral tritherapy not modified for = 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from NNRTI = efavirenz, rilpivirine, etravirine, doravirine PI/r = atazanavir/r ou darunavir/r INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir
Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
ANRS, Emerging Infectious Diseases

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of participants with HBV virological failure at 96 weeks. HBV virologoical failure is defined by 2 successive varial load = 10UI/ml 96 weeks
Secondary • HBV virological success rate at 48 weeks HBV virological success is defined by a viral load =10 UI/ml at Week 48
Secondary • HIV virological success rate at 48 and 96 weeks HIV virological success is defined by a viral load = 50 cp/ml At week 48 and week 96
Secondary • Time to virological failure (rebound HBV and/or HIV viral load) between Week 0 and Week96
Secondary • The rate of participants with at least one HBV viral load blip until W48 and until W96 a blip is defined by a HBV viral load >10UI/mL followed by a control value = 10UIml At week 48 and week 96
Secondary • Selection of HBV resistance mutations at the time of virological failure between Week 0 and Week 96
Secondary • Incidence of grade 3 or higher adverse events of grade 3 or higher, incidence of adverse events and incidence of strategy discontinuation of the strategy at W48 and W96 At week 48 and week 96
Secondary • Evolution of CD4 from W0 to W48 and W96 Week 0 to Week 48 and week 96
Secondary • Evolution of total cholesterol from W0 to W48 and W96 from Week 0 to Week 48 and Week 96
Secondary • Evaluation of the adherence by self-reported questionnaire without analysis scale at Week 0, Week 12, Week 24, Week 48, Week 72 and Week 96
Secondary • Evaluation of quality of life using the Pro-Qol self-questionnaire without analysis scale at Week 0, Week 12, Week 24, Week 48, Week 72 and Week 96
Secondary Evolution of CD8 T lymphocytes from W0 to W48 and W96 Week 0 to Week 48 and week 96
Secondary Evolution of the CD4/CD8 ratio from W0 to W48 and W96 Week 0 to Week 48 and week 96
Secondary Evolution of LDL-c from W0 to W48 and W96 from Week 0 to Week 48 and Week 96
Secondary Evolution of HDL-c from W0 to W48 and W96 from Week 0 to Week 48 and Week 96
Secondary Evolution of triglycerides from W0 to W48 and W96 from Week 0 to Week 48 and Week 96
Secondary Evolution of fasting blood sugar from W0 to W48 and W96 from Week 0 to Week 48 and Week 96
Secondary HBV virological success rate at 96 weeks between arms HBV virological success is defined by a viral load =10 UI/ml at Week 96
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2